Skip to main content
. 2018 Aug 1;8(7):e021805. doi: 10.1136/bmjopen-2018-021805

Table 2.

Distribution of clinical and tumour characteristics by ER status and receipt of tamoxifen among the 5959 participants in a population-based cohort of premenopausal women diagnosed with first primary breast cancer, ProBe CaRe study

Patient and tumour characteristics ER+/TAM+ ER−/TAM−
N % N %
Total 4600 100 1359 100
Age at diagnosis
 <35 222 4.8 182 23
 35–39 487 11 229 27
 40–44 1123 24 321 24
 45–49 1668 36 385 28
 50+ 1100 24 242 18
Menopausal status at diagnosis
 Premenopausal 4600 100 1359 100
Stage at diagnosis
 Stage I 1184 26 402 29.6
 Stage II 2476 54 702 51.7
 Stage III 917 20 246 18.1
 Unknown stage 23 0.5 9 0.7
Tumour size
 <2 mm 2646 58 677 50
 2≤5 mm 1780 39 632 47
 >5 mm 156 3.4 44 3.2
 Unknown 18 0.4 6 0.4
No of metastatic lymph nodes
 0 1704 37 695 51
 1 1148 25 238 17
 2 583 13 116 9
 3+ 1152 25 306 23
 Unknown 13 0.3 4 0.3
Lymph node evaluation
 No 8 0.2 3 0.2
 Yes 4592 100 1356 100
Histological grade
 Unsuitable 10 0.2 13 1
 I 955 21 21 1.5
 II 2391 52 216 16
 III 950 21 884 65
 Unknown 294 6.4 225 17
Type of primary surgery
 Mastectomy 2033 44 627 46
 Lumpectomy 2567 56 732 54
Progesterone receptor status
 PR− 383 8.3 1121 83
 PR+ 2680 58 19 1.4
 Unknown/not measured 1537 33 219 16
HER2 status
 HER2− 2887.00 63 692 51
 HER2+ 619 14 354 26
 Unknown/not measured 1094 24 313 23
Intention to treat with chemotherapy
 No 144 3 14 1
 Yes 4456 97 1345 99
Chemotherapy
 No 437 9 109 8
 Yes 4163 91 1250 92
Intention to treat with tamoxifen
 No 70 1.5 1351 99
 Yes 4530 98 8 0.6
Radiation therapy
 No 655 14 267 20
 Yes 3945 86 1092 80
Anti-HER2 therapy
 No 2887 63 692 51
 Yes 619 13 354 26
 Unknown 1094 24 313 23
Recurrence
 No 4204 91 1143 84
 Yes 396 8.6 216 16
Another malignancy
 No 4544 99 1341 99
 Yes 56 1.2 18 1.3
Dead at end of follow-up
 No 4239 92 1115 82
 Yes 361 8 244 18
Charlson Comorbidity Score
 0 4587 99 1344 99
 1 4 0.1 4 0.3
 2 2 0 3 0.2
 3+ 7 0.2 8 0.6

ER, oestrogen receptor; HER, human epidermal growth factor receptor 2; ProBe CaRe, Predictors of Breast Cancer Recurrence; PR, progesterone receptor; TAM, tamoxifen therapy.